NCT00972777

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 474 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.

Conditions

• Bacterial Conjunctivitis

Interventions

Type	Name	Description
DRUG	Besifloxacin	Besifloxacin 0.6% administered into the study eye two times a day for three days.
DRUG	Vehicle (Placebo)	Vehicle administered to the study eye two times a day for three days.

Timeline

• Start date: 2009-10-01
• Primary completion: 2010-10-01
• Completion: 2011-02-01
• First posted: 2009-09-09
• Last updated: 2012-03-29
• Results posted: 2012-03-29

Locations

1 site across 1 country: United States